IP Library Granted Patent US 6,955,819
Granted Patent B2
US 6,955,819 · App. 09/796,250 · Granted Oct 18, 2005

Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,955,819
App. No.
09/796,250
Granted
Oct 18, 2005
Kind
B2
Abstract

The present invention is directed toward an apparatus to rapidly deliver a drug to a patient The invention comprises a drug beneath a patient's skin in a drug depot site. A heating component is placed near the drug depot site and generates heat in and near the drug depot site. A control component connected to the heating component is used to control the magnitude and duration of heat generated by the heating component.

Claims (40)

1. A system for rapidly delivering a drug to a patient comprising:

a drug in a drug depot site, wherein said drug depot site comprises at least one of skin and sub-skin tissues;

a heating component to generate heat for heating the drug depot site; and

a control component capable of controlling the magnitude and duration of heat generated by the heating component to achieve selective, precise, on-demand delivery of said drug from said drug depot site.

2. The system of claim 1 , wherein said drug is in controlled release formulation.

3. The system of claim 1 , wherein the drug depot site is disposed within the skin tissues.

4. The system of claim 1 , wherein the drug depot site is disposed within the sub-skin tissues.

5. The system of claim 1 , wherein the drug is injected into the skin.

6. The system of claim 1 , wherein the drug is implanted into the skin.

7. The system of claim 1 , wherein the drug depot site comprises an extra bolus of drug delivered into the patient's body.

8. The system of claim 1 , wherein the drug is absorbed transdermally into the skin.

9. The system of claim 1 , wherein the heating component is capable of generating heat when supplied with electric current.

10. The system of claim 9 , wherein the control component receives a temperature signal from a temperature sensor proximate to the skin.

11. The system of claim 10 , wherein the control component adjusts the electric current to the heating component according to the temperature sensor.

12. The system of claim 9 , wherein the control component has settings that correspond to pre-determined electric power and heating time combinations.

13. The system of claim 9 , wherein the control component also has mechanism to lockout a length of time in which the device generates no heat during drug administration.

14. The system of claim 9 , wherein the control component is a mechanism that allows the patient to trigger delivery of a pre-determined amount of bolus drug from the depot site.

15. The system of claim 9 , wherein the control component is activated using a button.

16. The system of claim 9 , wherein the control component is pre-programmed to send an electric current with predetermined magnitude through a wire to the heating component for a pre-determined length of time.

17. The system of claim 16 , wherein the magnitude and the pre-determined length of time of the current produce a temperature increase at the skin for a pre-determined length of time that releases a pre-determined amount of the drug from the depot site.

18. The system of claim 16 , wherein the magnitude of the current is designed to produce several heating temperature vs. time profiles to accommodate different needs.

19. The system of claim 1 , wherein the control component safely and effectively delivers the bolus drug from sub-skin tissues by heating.

20. The system of claim 1 , wherein the heating component is preferably an electric heating component.

21. The system of claim 1 , further comprising a microprocessor in conjunction with the electric heating component.

22. The system of claim 1 , wherein the electric heating component and control component are connected by electric wires.

23. The system of claim 1 , wherein the heating component has a temperature sensor that measures the temperature at the drug patch and transmits the measure temperature to the control component to regulate the heating temperature.

24. The system of claim 1 , wherein the heating component has a layer of thermal insulating material on the side not in contact with the drug patch for minimizing heat loss.

25. The system of claim 1 , wherein the control component has a plurality of settings for controlling heat, each setting delivering a different amount of heating energy to the skin site.

26. The system of claim 12 , wherein the electric power associated with each said setting is pre-determined.

27. The system of claim 1 , wherein the drug in the drug depot site is delivered into the skin from a transdermal drug patch.

28. The system of claim 27 , wherein the drug patch is an analgesic drug patch.

29. The system of claim 27 , wherein said patch is applied on the skin of the patient for predetermined period to create a depot site.

30. The system of claim 27 , wherein further comprising means for releasably affixing the heating component to the drug patch.

31. The system of claim 30 , wherein the heating component and the drug patch have areas with corresponding loop and hook fasteners.

32. The system of claim 30 , wherein means for affixing the heating component to the drug patch can only be affixed in a prescribed orientation.

33. The system of claim 30 , wherein means for affixing the heating component comprises to an adhesive with appropriate tackiness and reusability.

34. The system of claim 1 , wherein said heating component is an exothermic oxidation heating patch.

35. The system of claim 34 , wherein the exothermic oxidation heating patch comprises a heating area covers a portion of the drug patch area.

36. The system of claim 34 , wherein the heating component is a disposable heating component.

37. The system of claim 1 , wherein the drug is selected from the group of: analgesics, anesthetics, anti-arthritis drugs, anti-inflammatory drugs, anti-migraine drugs, cardiovascularly active drugs, smoke cessation drugs, hormones, androgen, estrogen, non-steroidal anti-inflammatory agents, anti-hypertensive agents, analgesic agents, anti-depressants, antibiotics, anti-cancer agents, local anesthetics, antiemetics, anti-infectants, contraceptives, anti-diabetic agents, steroids, anti-allergy agents, anti-migraine agents, agents for smoking cessation, anti-obesity agents, nicotine, testosterone, estradiol, nitroglycerin, clonidine, dexamethasone, wintergreen oil, tetracaine, lidocaine, fentanyl, sufentanil, alfentanil and other potent mu-receptor agonists, progestrone, insulin, Vitamin A, Vitamin C, Vitamin E, prilocaine, bupivacaine, sumatriptan, scopolamine and dihydroergotamine.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded May 17, 2023
From: PALADIN LABS INC.
To: NUVO RESEARCH INC.
Reel/Frame 063695/0543 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2016
From: NUVO RESEARCH INC.
To: CRESCITA THERAPEUTICS INC.
Reel/Frame 040485/0021 →
RELEASE OF SECURITY INTEREST Recorded Jan 8, 2015
From: PALADIN LABS INC.
To: NUVO RESEARCH INC.
Reel/Frame 034664/0991 →
GENERAL SECURITY AGREEMENT Recorded Aug 20, 2012
From: NUVO RESEARCH INC.
To: PALADIN LABS INC.
Reel/Frame 028816/0225 →
CONFIRMATION OF ASSIGNMENT Recorded Jul 12, 2012
From: NUVO RESEARCH AMERICA, INC.
To: NUVO RESEARCH INC.
Reel/Frame 028549/0771 →
CONFIRMATION OF ASSIGNMENT Recorded Jul 10, 2012
From: ZARS PHARMA, INC.
To: NUVO RESEARCH AMERICA, INC.
Reel/Frame 028541/0011 →
MERGER Recorded Jul 6, 2012
From: ZARS, INC.
To: ZARS PHARMA, INC.
Reel/Frame 028504/0064 →